Home

Our Technology

Innovative Chemistry
Transformative Therapies

About us

What We Do

We’re a biotech company committed to stemming the prescription drug abuse epidemic.

Investment

Long Term
Opportunity

Events & Presentations

Special Meeting of Stockholders Find Out More

Events & Presentations

Ensysce Corporate Overview Find Out More

Events & Presentations

2022 Annual Meeting of Stockholders Find Out More
Ensysce Biosciences releases updated investor presentation ahead of corporate update call. Read More
Ensysce Biosciences provides business update and reports second quarter 2022 financial results. Read More
Ensysce Biosciences announces completion of $8 million convertible note financing. Read More
Ensysce Biosciences announces positive Bioequivalence (BE) study data of novel “TAAP” opioid PF614 and provides timing of corporate update call Read More
Dr. Vince Clinical Research Announces Dosing of Ensysce’s PF614 Compound in Human Abuse Read More

Our Team

Brilliant minds
and vision

We’re proud to say our team is made up of just that — people and minds both driven by passion and full of potential. Our company is led by a team of executives and directors with vast experience and proven track records in pain, drug development and commercialization.

D. Lynn Kirkpatrick, PHD

Chief Executive Officer

Richard Wright, MSE, MBA

Chief Business Officer

Dave Humphrey

Chief Financial Officer

Bill Schmidt

Chief Medical Officer.

Jeffrey Millard, PHD

Chief Operating Officer

Geoff Birkett

Chief Commercial Officer

Linda Pestano

Chief Development Officer